Allakos Inc. (NASDAQ:ALLK – Get Rating)’s stock price was down 3% during trading on Monday . The company traded as low as $7.40 and last traded at $7.51. Approximately 324,981 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 827,627 shares. The stock had previously closed at $7.74.
Allakos Price Performance
The stock’s 50 day moving average price is $7.64 and its 200 day moving average price is $5.92.
Allakos (NASDAQ:ALLK – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.25. On average, sell-side analysts anticipate that Allakos Inc. will post -5.27 earnings per share for the current year.
Institutional Trading of Allakos
Allakos Inc, a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
- Get a free copy of the StockNews.com research report on Allakos (ALLK)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.